Ending HIV Transmissions by 2020

A look at the current state of HIV health care.

Historically, infection by HIV (human immunodeficiency virus) was considered to be a death sentence. However, significant medical advances have allowed HIV positive people to lead healthy lives with treatment. AIDS (acquired immunodeficiency syndrome) is no longer the norm in Australia.

The NSW HIV Strategy 2016-2020 aims “to virtually eliminate HIV transmission in NSW by 2020”. With improving treatment and prevention methods, we have the resources to achieve this. This includes HIV Pre-Exposure Prophylaxis (PrEP).

On April 1, 2018, PrEP was listed on the Pharmaceutical Benefits Scheme (PBS). This ensures access to a highly effective HIV prevention method. A 30 day supply costs $39.50 or $6.40 if eligible for a concession on the PBS.

People at a higher risk of HIV infection under the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) Guidelines are eligible. They need to be Australian residents 18 or older, have a current Medicare card and have a negative HIV test result. International students may also qualify if their country has an appropriate Reciprocal Health Care Agreement with Australia.

People at higher risk of HIV infection include sexually active transgender, gay and bisexual men and heterosexual people whose partner is HIV positive without an undetectable viral load (UVL).

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below